Adlai Nortye(ANL) globenewswire.com·2024-05-24 01:03Core Insights - Adlai Nortye Ltd. is set to present promising preliminary data on its drug AN0025 in combination with definitive chemoradiotherapy for treating unresectable locally advanced or locally recurrent esophageal cancer at the ASCO Annual Meeting in Chicago from May 31 to June 4, 2024 [1][3] Company Overview - Adlai Nortye is a clinical-stage biotechnology company focused on developing innovative cancer therapies, with R&D centers in New Jersey, US, and Hangzhou, China [4] - The company has a robust pipeline of six drug candidates aimed at addressing various tumor types [4] - Adlai Nortye aims to become a global leader in oncology therapies through a combination therapy strategy, with the goal of transforming deadly cancers into chronic and eventually curable diseases [5] Clinical Study Details - AN0025 is a selective EP4 inhibitor that modulates macrophages and immunosuppressive myeloid cells in the tumor microenvironment, showing synergistic antitumor efficacy when combined with chemoradiotherapy in previous trials [2] - The ongoing AN0025S0104 study is a Phase Ib, single-arm, open-label, multicenter trial evaluating the safety and feasibility of AN0025 plus definitive chemoradiotherapy for esophageal cancer [2][3] Strategic Partnerships - The company has established a global management team and scientific advisory board to guide its R&D and business development efforts [5] - Adlai Nortye is actively seeking partnerships with leading pharmaceutical companies like Eisai and Novartis to enhance the potential of its pipeline programs [5]